News
Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430)Trial to evaluate efficacy and safety of lerodalcibep (LIB003) and inclisiran in high risk CVD patients (LIBerate-VI) (NCT05004675)Study of efficacy and safety of lerodalcibep (LIB003) in patients with CVD on statins requiring additional LDL-C reduction (LIBerate-CVD) (NCT04797247)Study to assess the efficacy and safety of lerodalcibep (LIB003) in patients with HeFH on oral lipid therapy needing further LDL-C reduction (LIBerate-FH) (NCT04797104)Study of long term efficacy and safety of lerodalcibep (LIB003) in patients with CVD or high risk for CVD needing further LDL-C Reduction (LIBerate-HR, NCT04806893)Phase 3 study to evaluate the efficacy and safety of lerodalcibep (LIB003) with evolocumab in HoFH (NCT04034485)
Hot off the Press Remembering Akira Endo and the beginning of the ‘statin era’
Hot Topics
From the 20th Closed Scientific Expert Meeting of the Editorial Board
CRISPR engineering of wild-type alleles versus millions of years of human evolutionProfessor Steve FarberWatch now
The statin intolerant patient with ASCVD: What is your therapeutic strategy?Professor Ioanna Gouni-BertholdWatch now
Slide Resource Programme
Find out more »
News from the Trials
Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
- CLEAR Outcomes confirms bempedoic acid benefits for recurrent CV events
- FOURIER-OLE shows greater MACE reduction in multivessel disease
- PACMAN-AMI: Sub study on alirocumab plaque effects
Trial Resources
For expert analysis and insights
Most viewed
Study of efficacy and safety of lerodalcibep (LIB003) in patients with CVD on statins requiring additional LDL-C reduction (LIBerate-CVD) (NCT04797247)
Phase 3 study to evaluate the efficacy and safety of lerodalcibep (LIB003) with evolocumab in HoFH (NCT04034485)
Study to assess the efficacy and safety of lerodalcibep (LIB003) in patients with HeFH on oral lipid therapy needing further LDL-C reduction (LIBerate-FH) (NCT04797104)
Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430)
Open label extension to evaluate the longer term efficacy of lerodalcibep (LIB003) (NCT03847974)
Trial to evaluate efficacy and safety of lerodalcibep (LIB003) and inclisiran in high risk CVD patients (LIBerate-VI) (NCT05004675)
Study to evaluate efficacy and safety of LIB003 in patients on lipid-lowering therapy needing additional LDL-C reduction (NCT03549260)
Remembering Akira Endo and the beginning of the ‘statin era’
Trial to evaluate efficacy and safety of lerodalcibep (LIB003), evolocumab and alirocumab in patients at high risk CVD (LIBerate-H2H) (NCT04790513)
Study of long term efficacy and safety of lerodalcibep (LIB003) in patients with CVD or high risk for CVD needing further LDL-C Reduction (LIBerate-HR, NCT04806893)
From the Editors
Lerodalcibep: What does LIBerate-HeFH tell us?
Professor Derick Raal discusses lerodalcibep data from the LIBerate-HeFH trial and explains what the results mean to practising clinicians.
Related content:
Congress Highlights
Upcoming Event
In Case You Missed It
PCSK9 inhibition with a novel fusion protein
Derick Raal, University of the Witwatersrand, Johannesburg, South Africa, presents efficacy and safety data from Phase 3 trials of lerodalcibep.
Oral PCSK9 inhibition: Clinical update
Christie Ballantyne, Baylor College of Medicine, Houston, USA, reports Phase 2b results with the oral PCSK9 inhibitor, MK-0616.
News from ACC 2024
View ACC.24 reports »About PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower LDL-C, which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature CV death and disability.Read more »
Increasing awareness, knowledge and understanding of elevated serum TGs in the development of CVD and pancreatitis and stimulating research of novel therapeutic strategies.
JOIN TODAYMeet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the Sorbonne University
Prof Henry GinsbergIrving Professor of Medicine, Columbia University
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
